NeuraLight has joined the RADIEMS (Reserve Against Disability in Early MS) cohort longitudinal study at the Icahn School of Medicine at Mount Sinai, led by Professor Fred Lublin, a world leader in Multiple Sclerosis, and Dr. Ilana Katz-Sand as a prinicipal investigator.
The Reserve against Disability in Early MS (RADIEMS) cohort study is an NIH-funded prospective study of risk and protective factors related to disease and disability progression in persons with early relapsing-remitting multiple sclerosis (MS), with a focus on cognitive function.
In this study, NeuraLight assessment will be added to investigate the relationships between oculometric measures (OMs) and traditional outcome measures of physical and cognitive dysfunction in multiple sclerosis (MS).
This initiative reflects NeuraLight’s broader mission to transform neurology and care through precise, AI-driven biomarkers.